Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

January 23rd 2025

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Dr Jurczak on the Role of Nemtabrutinib in R/R Follicular Lymphoma Management

January 23rd 2025

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.

Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL

January 23rd 2025

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL

January 22nd 2025

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML

January 22nd 2025

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer

January 22nd 2025

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Dr Brentjens on Efforts to Expand CAR T-Cell Therapy Beyond B-Cell Malignancies

January 21st 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

January 21st 2025

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Dr Park on the FDA Approval of Obe-Cel in Adult R/R ALL

January 21st 2025

Jae Park, MD, discusses the FDA approval of obe-cel for adult patients with relapsed or refractory acute lymphoblastic leukemia.

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

January 20th 2025

Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors.

Dr Krop on the Efficacy and Tolerability of SHR-A1811 in Advanced HER2+ Breast Cancer

January 20th 2025

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer

January 20th 2025

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

FDA Clears Diagnostic Assay for B-Cell Lymphoma

January 20th 2025

The FDA has granted 510(k) clearance for the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to assist pathologists in diagnosing B-cell lymphoma

Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma

January 17th 2025

Muhamed Baljevic, MD, discusses the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS

January 17th 2025

Monzr M. Al Malki, MD, discusses the potential use of TSC-100 and TSC-101 following allogeneic stem cell transplant in patients with AML, ALL or MDS.

Dr Philip on Considerations for Selecting First-Line Treatment in Newly Diagnosed, Low-Risk GI NETs

January 16th 2025

Philip Philip, MD, discusses considerations for selecting first-line treatment for newly diagnosed, low-risk gastrointestinal neuroendocrine tumors.

Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer

January 15th 2025

Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

January 15th 2025

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

January 15th 2025

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer

January 15th 2025

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.